{"entity":{"id":"etx-19477","kind":"drug","name":"ETX-19477","aka":[],"tldr":"ETX-19477 is an experimental small molecule from 858 Therapeutics, in phase 1 trials for advanced solid tumours, BRCA-mutated platinum-resistant ovarian cancer and BRCA-mutated HR-positive, HER2-negative unresectable or metastatic breast cancer.","summary":"ETX-19477 is a small molecule (oral) from 858 Therapeutics. An oral, selective inhibitor of PARG (poly(ADP-ribose) glycohydrolase) that exploits cancer cell vulnerabilities related to replication stress and defects in replication fork protection. Its furthest stage is phase 1, for advanced solid tumours, BRCA-mutated platinum-resistant ovarian cancer and BRCA-mutated HR-positive, HER2-negative unresectable or metastatic breast cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 NCT06395519 recruiting per v2 API; FDA Fast Track designations January and August 2026 (company news page). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"858 Therapeutics: 8five8tx.com","url":"https://www.8five8tx.com/"},{"label":"858 Therapeutics: 8five8tx.com","url":"https://8five8tx.com/news/"},{"label":"858 Therapeutics: 8five8tx.com","url":"https://8five8tx.com/news/"},{"label":"858 Therapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06395519"},{"label":"ClinicalTrials.gov: trials of ETX-19477","url":"https://clinicaltrials.gov/search?intr=ETX-19477"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parg"],"drugs":[],"companies":["858-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06395519"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"ETX-19477","modality":"Small molecule (oral)","mechanism":"An oral, selective inhibitor of PARG (poly(ADP-ribose) glycohydrolase) that exploits cancer cell vulnerabilities related to replication stress and defects in replication fork protection.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/etx-19477/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parg","kind":"target","name":"PARG","route":"/targets/parg/"}],"company":[{"id":"858-therapeutics","kind":"company","name":"858 Therapeutics","route":"/companies/858-therapeutics/"}],"trial":[{"id":"nct06395519","kind":"trial","name":"A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies","route":"/trials/nct06395519/"}]}}